Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand, Mexico, China, Russia, Zimbabwe, Papua New Guinea, and internationally. More Details
+ 1 more risk
Excellent balance sheet with limited growth.
Share Price & News
How has TruScreen Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRU is more volatile than 90% of NZ stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: TRU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of NZ stocks.
7 Day Return
NZ Medical Equipment
1 Year Return
NZ Medical Equipment
Return vs Industry: TRU exceeded the NZ Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: TRU exceeded the NZ Market which returned 10.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is TruScreen Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of TruScreen Limited (NZSE:TRU)?
9 months ago | Simply Wall StIf You Had Bought TruScreen (NZSE:TRU) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today
11 months ago | Simply Wall StWhat Kind Of Shareholders Own TruScreen Limited (NZSE:TRU)?
Is TruScreen Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the XO Medical Equipment industry average.
PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRU is good value based on its PB Ratio (4.2x) compared to the XO Medical Equipment industry average (6.8x).
How is TruScreen Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRU's revenue (36.2% per year) is forecast to grow faster than the NZ market (5.1% per year).
High Growth Revenue: TRU's revenue (36.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRU's Return on Equity is forecast to be high in 3 years time
How has TruScreen Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRU is currently unprofitable.
Growing Profit Margin: TRU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (41.9%).
Return on Equity
High ROE: TRU has a negative Return on Equity (-51.05%), as it is currently unprofitable.
How is TruScreen Group's financial position?
Financial Position Analysis
Short Term Liabilities: TRU's short term assets (NZ$6.6M) exceed its short term liabilities (NZ$973.3K).
Long Term Liabilities: TRU's short term assets (NZ$6.6M) exceed its long term liabilities (NZ$49.4K).
Debt to Equity History and Analysis
Debt Level: TRU's debt to equity ratio (3.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TRU's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TRU has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 1.4% each year.
What is TruScreen Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Victoria Potarina is the Chief Executive Officer of TruScreen Group Limited (formerly known as TruScreen Limited) since March 02, 2020. She was Business Unit Director of the UK and Ireland Diabetes Car...
CEO Compensation Analysis
Compensation vs Market: Victoria's total compensation ($USD221.94K) is about average for companies of similar size in the NZ market ($USD232.93K).
Compensation vs Earnings: Insufficient data to compare Victoria's compensation with company performance.
|Chief Executive Officer||0.83yr||NZ$308.96k||no data|
|CFO & Company Secretary||2.17yrs||NZ$105.45k||0.028% |
|General Manager of Quality & Regulatory Compliance||2.5yrs||no data||0.024% |
|Chief Technology Officer||no data||no data||no data|
|Manager of Administration & Marketing||2.67yrs||no data||no data|
|Head of Cancer Department||no data||no data||no data|
|Head of Research & Development and Training Department||no data||no data||no data|
|Head of High Service Gynaecology Examination||no data||no data||no data|
Experienced Management: TRU's management team is considered experienced (2.3 years average tenure).
|Member of Medical Advisory Board||no data||no data||no data|
|Independent Non-Executive Director||7.17yrs||NZ$84.00k||0.56% |
|Chairman of Medical Advisory Board||1yr||no data||no data|
|Non-Executive Director||3.08yrs||NZ$74.00k||no data|
|Independent Non-Executive Director||0.33yr||no data||no data|
Experienced Board: TRU's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TRU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.5%.
TruScreen Group Limited's company bio, employee growth, exchange listings and data sources
- Name: TruScreen Group Limited
- Ticker: TRU
- Exchange: NZSE
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NZ$52.616m
- Shares outstanding: 362.87m
- Website: https://truscreen.com
- TruScreen Group Limited
- Equitable House
- Level 6
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TRU||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Nov 2014|
|TRU||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Nov 2014|
Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand, Mexico, China, Russia, Zimbabwe, Papua New Guinea, and intern...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/26 06:01|
|End of Day Share Price||2021/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.